Psyence Group Inc.

Psyence Group Inc.

2903 views8 min read

Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination

Psyence Group
Psyence Group Inc.TORONTO, Jan. 16, 2024 -- Psyence Group Inc ("Psyence Group") (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that its subsidiary, Psyence Biomedical Ltd ("Pubco"), has entered into a definitive securities purc... Read More...
M & A25 views8 min read

Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp

Psyence Group
TORONTO, Nov. 15, 2023 -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration stat... Read More...
574 views6 min read

Psyence Production Expands Capability

Psyence Group
TORONTO, Oct. 30, 2023 -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), is pleased to provide the following update on Psyence Production. Psyence Production is a division of Psyence that oversees its psilocybin ... Read More...
Capital Raise667 views4 min read

Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement

Psyence Group
TORONTO, Aug. 21, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it has issued 1,056,441 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$126,773.... Read More...
1000 views8 min read

Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement

Psyence Group
VANCOUVER, British Columbia, Aug. 02, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (“Newcourt”) (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) toda... Read More...
130 views6 min read

Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Psyence Group
TORONTO, Jan. 24, 2023 -- Psyence Group Inc. (CSE: PSYG. |. OTCQB: PSYGF) (Psyence or the Company), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has entered into a partnership with Eden Labs LLC, (“Eden Labs”) a product development and extra... Read More...
122 views4 min read

Psyence Group Completes Export of Pharma Grade Psilocybin Extract to UK

Psyence Group
TORONTO, Jan. 20, 2023 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce that it has exported purified pharmaceutical grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation (“CDMO”) partner in the United Kingdom. The product was exported from Psyenc... Read More...
M & A602 views12 min read

Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp

Psyence Group
VANCOUVER, British Columbia, Jan. 09, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) formed for the purpose of acquir... Read More...
1181 views8 min read

Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care

Psyence Group
VANCOUVER, British Columbia, Dec. 15, 2022 -- Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF) (“Psyence” and, together with Filament, the “Companies”), a life science biotechnology company pioneering the use ... Read More...
620 views5 min read

Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor

Psyence Group
Psyence Group Inc.TORONTO, Dec. 14, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being is pleased to announce that it has closed the second tranche of its previously announced private placement o... Read More...
1107 views7 min read

GOODMIND™ Available for Sale in the United Kingdom and Europe – Exclusive Distribution Agreement Concluded With This Works

Psyence Group
TORONTO, Nov. 29, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), ente... Read More...
Capital Raise121 views4 min read

Psyence Group Announces Strategic Private Placement

Psyence Group
TORONTO, Nov. 10, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has received subscription agreements for gross proceeds of CAD$1.22 million from a consortium ... Read More...
473 views5 min read

Psyence Group Completes Export of Psilocybin Mushrooms to Portugal

Psyence Group
TORONTO, Sept. 29, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce that it has successfully exported medical grade psilocybin mushrooms to Psilo Pharma Inc. (“Psilo Pharma”), from its federally licensed ISO22000 certified production facility in Southern Africa, through its research... Read More...
1139 views4 min read

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Psyence Group
TORONTO, Sept. 22, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in Canada. Psilo Scientific, a wholly owned subsidiary of Filament Health Corp., is an exclusively natural psychedelic drug discovery and extraction company. Psyence ... Read More...
849 views4 min read

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Psyence Group
TORONTO, Sept. 19, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare pr... Read More...
994 views4 min read

Psyence Taps Another Pharma Exec to Drive its Clinical Program

Psyence Group
TORONTO, May 31, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce the appointment of Dr. Clive Ward-Able as the Medical Director of Psyence Group, effective immediately.... Read More...
42 views4 min read

Psyence Group Announces DTC Eligibility Approval in the U.S.

Psyence Group
TORONTO, Feb. 09, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the D... Read More...
861 views4 min read

Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility

Psyence Group
TORONTO, Feb. 07, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that its ISO22000 graded Psilocybin production facility has officially received International Organiza... Read More...
1281 views4 min read

Psyence looks to expand capital market opportunities in the UK and Europe

Psyence Group
TORONTO, Jan. 21, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is exploring capital market opportunities to access a broader pool of United Kingdom (“UK”) and European in... Read More...
1096 views4 min read

Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6

Psyence Group
TORONTO, Dec. 03, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that Psyence Chief Executive Officer, Neil Maresky, will be presenting at the virtual H.C. Wainwright ... Read More...
Capital Raise1172 views3 min read

Psyence Group Announces Private Placement

Psyence Group
TORONTO, Dec. 02, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is commencing a non-brokered private placement offering of up to CAD$2,000,000 of unsecured convertible pro... Read More...
924 views7 min read

Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out in South Africa’s Largest Coffee Retail Chain

Psyence Group
Company Broadens Revenue Generation InitiativesGOODMIND™Elevate your daily grind / GOODMIND™Elevate your daily grind / GOODMIND™TORONTO, Dec. 02, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-bein... Read More...
Financials138 views4 min read

Psyence Group Inc. files Q2 Unaudited Condensed Consolidated Interim Financial Statements and MD&A

Psyence Group
TORONTO, Nov. 26, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, announces that the Unaudited Condensed Consolidated Interim Financial Statements for the six months period ended September 30, 2021... Read More...
Calendar136 views3 min read

Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit

Psyence Group
TORONTO, Nov. 26, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit, a gathering of i... Read More...
24 views4 min read

Psyence Group Announces Commencement of Trading on OTCQB and DTC Eligibility of Common Shares in the United States Under the Ticker “PSYGF”

Psyence Group
TORONTO, Oct. 13, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that, effective today, its common shares have been approved for trading on the OTCQB® Venture Market (... Read More...
Joint VentureM & A432 views6 min read

Psyence Group and Pure Extracts Finalize “Pure Psyence,” A Joint Venture for the Development of Psychedelic Medicinal Mushroom Extracts

Psyence Group
A Canadian partnership with international ties to advance the field of psychedelic medicine globally with standardized extractsA leader in naturally-derived psilocybin for extraction, production of advanced formulations and clinical research TORONTO, Sept. 28, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) and Pure Ex... Read More...
737 views6 min read

Psyence Group Announces the Commencement of Online Sales and Distribution of “GOODMIND” Products

Psyence Group
TORONTO and CAPE TOWN, South Africa, Aug. 18, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce the commencement of online sales and distribution of its premium range of functional mush... Read More...
123 views6 min read

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial

Psyence Group
TORONTO, July 07, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce it has signed a partnership agreement with Clerkenwell Health (“Clerkenwell”). Clerkenwell is a leading psychedelic C... Read More...
918 views5 min read

Psyence Group Announces Appointment of New Chief Executive Officer

Psyence Group
TORONTO, June 28, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has appointed Dr. Neil Maresky as Chief Executive Officer. Dr. Maresky joins Psyence after just having  compl... Read More...
56 views6 min read

Psyence Group Corporate Update

Psyence Group
TORONTO, May 27, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function.Psyence ProductionPsyence is federally licensed to cultivate and export psilo... Read More...
73 views4 min read

The Psyence Group Announces its Formal Entry into Jamaica with the Incorporation of its Wholly Owned Subsidiary, Psyence Jamaica Limited

Psyence Group
TORONTO, June 08, 2021 -- Psyence Group Inc. (“Psyence” or the “Company”) (PSYG:CSE), a Canadian public biotechnology company with a global presence, is pleased to announce the incorporation, and operational commencement, of its wholly owned Jamaican subsidiary, “Psyence Jamaica Limited” (“Psyence Jamaica”).The Psyence Group has been oper... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!